Zeitschrift für Gastroenterologie, Table of Contents Z Gastroenterol 2019; 57(10): 1236-1238DOI: 10.1055/a-1014-8271 Mitteilungen der DGVS © Georg Thieme Verlag KG Stuttgart · New YorkStellungnahme zum Beschlussentwurf des G-BA zur Nicht-Änderung der Gesundheitsuntersuchungs-Richtlinie (GU-RL): Screening auf Hepatitis B Recommend Article Abstract Buy Article(opens in new window) Full Text References Literatur 1 Bundesministerium für Gesundheit and Bundesministerium für wirtschaftliche Zusammenarbeit und Entwicklung, Strategie zur Eindämmung von HIV, Hepatitis B und C und anderen sexuell übertragbaren Infektionen. Bis 2030 – Bedarfsorientiert · Integriert · Sektorübergreifend 2016 2 Wolffram I, Petroff D, Bätz O. et al. Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. Journal of Hepatology 2015; 62: 1256-1264 3 Heidrich B, Cetindere A, Beyaz M. et al. High prevalence of Hepatitis marker in immigrant populations: A prospective multicenter screening approach in a real world setting. Eur J Gastroenterol Hepatol 2014; 26: 1090-1097 4 Hampel A, Solbach P, Cornberg M. et al. Current seroprevalence, vaccination and predictive value of liver enzymes for hepatitis B among refugees in Germany. Bundesgesundheitsblatt – Gesundheitsforschung – Gesundheitsschutz 2016; 59: 578-583 5 Schmidt D, Kollan C, Haußig J. et al. Anhaltende Hepatitis-Ko-Infektionen und HBV-Impfbedarf bei HIV-infizierten Personen in Deutschland – Daten aus dem Hepatitis Screening in der HIV-1 Serokonverterstudie 2012–2016, in DÖAK 2017. Salzburg: 2017 6 Robert-Koch-Institut (RKI). Abschlussbericht der Studie „Drogen und chronischen Infektionskrankheiten in Deutschland“ (DRUCK-Studie). Berlin: Robert Koch Institut (RKI); 2016 7 Poethko-Muller C, Zimmermann R, Hamouda O. et al. Die Seroepidemiologie der Hepatitis A, B und C in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56: 707-715 8 Chou R, Dana T, Bougatsos C. et al. Screening for hepatitis B virus infection in adolescents and adults: a systematic review to update the U. S. Preventive Services Task Force recommendation. Ann Intern Med 2014; 161: 31-45 9 Hung TH, Tsai CC, Lee HF. Population-based study of Entecavir and long-term mortality in chronic hepatitis B-related decompensated liver cirrhosis. Clin Res Hepatol Gastroenterol 2019; S2210-S7401 10 Su TH, Hu TH, Chen CY. et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int 2016; 36: 1755-1764 11 Wu CY, Lin JT, Ho HJ. et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology 2014; 147: 143-151.e5 12 Wang X, Liu X, Dang Z. et al. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver 2019 Epub ahead of print 13 Papatheodoridis GV, Sypsa V, Dalekos G. et al. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. J Hepatol 2018; 68: 1129-1136 14 Tu T, Budzinska MA, Vondran FWR. et al. Hepatitis B Virus DNA Integration Occurs Early in the Viral Life Cycle in an In Vitro Infection Model via Sodium Taurocholate Cotransporting Polypeptide-Dependent Uptake of Enveloped Virus Particles. J Virol 2018; 92: e02007-17 15 Mason WS, Gill US, Litwin S. et al. HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant. Gastroenterology 2016; 151: 986-998.e4 16 Spencer FA, Iorio A, You J. et al. Uncertainties in baseline risk estimates and confidence in treatment effects. BMJ 2012; 345: e7401 17 Iorio A, Spencer FA, Falavigna M. et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ 2015; 350: h870 18 Robert-Koch-Institut (RKI). Impfquoten bei der Schuleingangsuntersuchung in Deutschland 2017. Epid Bull 2019; 18: 147-153 19 Haussig JM, Nielsen S, Gassowski M. et al. A large proportion of people who inject drugs are susceptible to hepatitis B: Results from a bio-behavioural study in eight German cities. Int J Infect 2018; 66: 5-13
